Immune checkpoint inhibitors, particularly those targeting programmed death-1 (PD-1) and cytotoxic T lymphocyte-associated antigen-4 (CTLA-4), have emerged as critical components of contemporary HCC research (7, 8). Here, CTLA4 is linked to hepatocellular carcinoma.